![Synthesis and evaluation of analgesic, anti-inflammatory and ulcerogenic activities of some triazolo- and 2-pyrazolyl-pyrido[2,3-d]-pyrimidines Cover](https://sciendo-parsed.s3.eu-central-1.amazonaws.com/6470747471e4585e08a9d7bc/cover-image.jpg)
References
- A. B. A. El-Gazzar, M. M. El-Enany and M. N. Mahmoud, Synthesis, Analgesic, anti-inflammatory and antimicrobial activity of some novel pyrimido[4,5-d]quinolin-4-ones, Bioorg. Med. Chem. 16 (2008) 3261-3273; DOI: 10.1016/j.bmc.2007.12.012.
- D. H. Boschelli, Z. Wu, S. R. Klutchko, H. D. Showalter, J. M. Hamby, G. H. Lu, T. C. Major, T. K. Dahring, B. Batley, R. L. Panek, J. Keiser, B. G. Hartl, A. J. Kraker, W. D. Klohs, B. J. Roberts, S. Patmore, W. L. Elliott, R. Steinkampf, L. A. Bradford, H. Hallak and A. M. Doherty, Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent selective platelet-derived growth factor receptor tyrosine kinase inhibitors, J. Med. Chem. 41 (1998) 4365-4377; DOI: 10.1021/jm980398y 50022-2623(98)00398-7.
- S. R. Natarajan, D. D. Wisnoski, J. E. Thompson, E. A. O'Neill and S. J. O'Keefe, p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones, Bioorg. Med. Chem. Lett. 16 (2006) 4400-4404; DOI: 10.1016/j.bmcl. 2006.05.045.
- C. B. Vu, G. P. Luke, N. Kawahata, W. C. Shakespeare, Y. Wang, R. Sundara-Moorthi, C. A. Metcalf, T. P. Keenan, S. Pradeepan, E. Corpuz, T. Merry, R. S. Bohacek, D. C. Dalgarno, S. S. Narula, M. R. van Schravendijk, M. K. Ram, S. Adams, S. Liou, J. A. Keats, S. M. Violette, W. Guan, M. Weigele and T. K. Sawyer, Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of src tyrosine kinase as novel antiresorptive agents, Bioorg. Med. Chem. Lett. 13 (2003) 3071-3074; DOI: 10.1016/S0960-894X(03)00649-8.
- A. J. Kraker, B. G. Hartl, A. M. Amar, M. R. Barvian, H. D. Hollis Showalter and C. W. Moore, Biochemical and cellular effect of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors, Biochem. Pharmacol. 60 (2000) 885-898.
- M. Barvian, R. J. Booth, J. Quin III., J. T. Repine, D. J. Sheehan, P. L. Toogood, S. N. Vanderwel and H. Zhou, 2-(Pyridin-2-yl-amino)-pyrido[2,3-d]pyrimidin-7-ones, PCT. Int. Appl. (2007), (C07D401/14; A61K31/444) WO 7208489.
- H. B. Arzeno, J. J. Chen, J. P. Dunn, D. M. Goldstein and J. A. Lim, Preparation of 7-oxopyridopyrimidines as P38 MAP kinase inhibitors, PCT. Int. Appl. (2002), WO 200218379.
- R. J. Booth, A. Chatterjee and T. C. Malone, Pyridopyrimidinone derivatives for treatment of neurodegenerative disease, PCT. Int. Appl. (2001), WO 2001055148.
- S. Tu, J. Zhang, X. Zhu, J. Xu, Y. Zhang, Q. Wang, R. Jia, B. Jiang and J. Zhang, New potential inhibitors of cyclin-dependent kinase: Design and synthesis of pyrido[2,3-d]pyrimidine derivatives under microwave irradiation, Bioorg. Med. Chem. Lett. 16 (2006) 3578-3581; DOI: 10.1016/j. bmcl.2006.03.084.
- M. Hájek, N. Matulová, I. Votruba, A. Holý and E. Tlouš'tova, Inhibition of human, telomerase by diphosphates of acyclic nucleoside phosphonates, Biochem. Pharmacol. 70 (2005) 894-900; DOI: 10.1016/j.bcp.2005.06.07.
- J. J. Chen, J. P. Dunn, D. M. Goldstein and C. M. Stahl, Preparation of 2,6-disubstituted 7-oxopyrido[2,3-d]pyrimidines for treating P38 mediated disorders, PCT. Int. Appl. (2002) WO 2002064594.
- S. R. Kanth, G. V. Reddy, K. H. Kishore, P. S. Rao, B. Narsaiah and U. S. N. Murthy, Convenient synthesis of novel 4-substituted amino-5-trifluoromethyl-2,7-disubstituted pyrido[2,3-d] pyrimidines and their antibacterial activity, Eur. J. Med. Chem. 41 (2006) 1011-1016; DOI: 10.1016/j.ejmech. 2006.03.028.
- V. Darias, S. S. Abdallah, M. L. Tello, L. D. Delgado and S. Vega, NSAI activity study of 4-phenyl-2-thioxo-benzo[4,5]thieno[2,3-d]pyrimidines derivatives, Arch. Pharm. 327 (1994) 779-383; DOI: 10.1002/ardp. 19943271205.
- L. Cordeu, E. Cubedo, E. Bandres, A. Rebollo, X. Saenz, H. M. Chozes, V. Dominquez, M. Echeverria, B. Mendivil, C. Sanmartin, J. A. Palop, M. Font and J. Garcia-Foncillas, Biological profile of new apoptotic agents based on 2,4-pyrido[2,3-d]-pyrimidine derivatives, Bioorg. Med. Chem. 15 (2007) 1659-1669; DOI: 10.1016/j.bmc.2006.12.010.
- M. Zink, H. Lanig and R. Troschütz, Structural variations of piritrexim, a lipophilic inhibitor of human dihydrofolate reductase: synthesis, antitumor activity and molecular modeling investigations, Eur. J. Med. Chem. 39 (2004) 1079-1088; DOI: 10.1016/j.ejmech.2004.09.001.
- R. A. Newberry and B. J. Bushell, Thiazole derivatives U.S. 3, 979, 402 (Cl.260-302R; Co7 D227122). 07 Sep. (1976), Brit. Appl. 748, 870, 27 Feb. (1974); ref. Chem. Abstr. 86 (1977) 29795z.
- M. Yu. Gavrilov, L. G. Mardanova, V. E. Kolla and M. E. Konshin, Synthesis and anti-inflammatory and analgesic activities of 2-arylamino-5,6,7,8-tetrahydroquinoline-3-carboxamides, J. Pharm. Chem. 22 (1988) 554-556; DOI: 10.1007/BF00763528.
- A. B. A. El-Gazzar, A. M. Gaafar, H. N. Hafez and A. M. Abdel-Fattah, Regioselective synthesis and reactions of polynuclear heterocyclic derived from pyrido[2,3-d]pyrimidines, with new ring system, Phosphorus, Sulfur, Silicon 182 (2007) 369-403; DOI: 10.1080/10426500600919967.
- Guide for the Care and Use of Animals (Eds. E. D. Olfert, B. M. Cross and A. A. McWilliam), 2nd ed, Vol. I, Canadian Council on Animal Care, Ottawa 1993, p. 211.
- C. A. Winter, E. A. Risley and G. W. Nuss, Carragenan-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs, Proc. Soc. Exp. Biol. Med. 111 (1962) 544-547.
- O. O. Adeyemi, O. S. Okpo and O. J. Okpaka. The analgesic effect of the methanolic extract of acanthus montanus, Ethnopharmacology 90 (2004) 45-48; DOI: 10.1016/j.jep.2003.09.021.
- V. Cioli, S. Putzolu, V. Rossi, S. P. Barrcellona and C. Corradino, The role of direct tissue contact in the production of gastro-intestinal ulcers by anti-inflammatory drugs in rats, Toxicol. Appl. Pharmacol. 50 (1979) 283-289.